Edesa Biotech (EDSA) Retained Earnings (2013 - 2026)
Edesa Biotech (EDSA) posted Retained Earnings of $15.1 million for Q4 2025, up 2.52% sequentially from $14.8 million in Q3 2025, and up 6.69% YoY from $14.2 million in Q4 2024.
Edesa Biotech (EDSA) Retained Earnings (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Retained Earnings for 13 years, with the latest figure at $15.1 million in Q4 2025.
- Quarterly Retained Earnings rose 6.69% year-over-year to $15.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.1 million (up 6.69% YoY) and the FY2025 annual result came in at $14.8 million, up 6180.92% from the prior year.
- Retained Earnings climbed to $15.1 million in Q4 2025 per EDSA's latest filing, from $14.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $15.1 million in Q4 2025 and troughed at -$63.6 million in Q2 2025.
- A 5-year average of -$11.1 million and a median of -$210330.0 in 2021 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings plunged 30200.16% in 2024, then soared 6180.92% in 2025.
- Over 5 years, Retained Earnings stood at $5.5 million in 2021, then soared by 126.57% to $12.4 million in 2022, then rose by 6.49% to $13.2 million in 2023, then climbed by 7.21% to $14.2 million in 2024, then increased by 6.69% to $15.1 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $15.1 million, $14.8 million, and -$63.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | -77.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.90 Mn |
| Dec 31, 2025 | 15.12 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Jun 30, 2025 | -63.60 Mn |
| Mar 31, 2025 | -61.86 Mn |
| Dec 31, 2024 | 14.18 Mn |
| Sep 30, 2024 | -242,613.00 |
| Jun 30, 2024 | -57.63 Mn |
| Mar 31, 2024 | -226,403.00 |
| Dec 31, 2023 | 13.22 Mn |
| Sep 30, 2023 | -52.42 Mn |
| Jun 30, 2023 | -190,187.00 |
| Mar 31, 2023 | -230,026.00 |
| Dec 31, 2022 | 12.42 Mn |
| Sep 30, 2022 | 11.18 Mn |
| Jun 30, 2022 | 12.93 Mn |
| Mar 31, 2022 | -35.44 Mn |
| Dec 31, 2021 | 5.48 Mn |
| Sep 30, 2021 | -26.50 Mn |
| Jun 30, 2021 | -22.81 Mn |